Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06961721 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IV Clinical Trial to Evaluate the Immunogenicity and Safety of a Live Attenuated Herpes Zoster Vaccine in Adults Aged 40 Years and Older

StatusNot Yet Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 8, 2025 (before its estimated July 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Study First Submitted
To evaluate the immunogenicity 42 days after vaccination with the live attenuated herpes zoster vaccine. To evaluate the safety of the live attenuated herpes zoster vaccine.
Trial Details
NCT Number NCT06961721
Lead Sponsor Changchun BCHT Biotechnology Co.
Collaborators: Inner Mongolia Center for Disease Control and Prevention, Center for Disease Control and Prevention, Fujian
Conditions
(from sponsor)		 Prevention of Herpes Zoster
Related terms Herpes Zoster
Enrollment 600 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov